Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05571059 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05571059 · ClinicalTrials.gov record · last posted 2026-03-05

Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)

StatusRecruiting
PhasePhase 2
Started2024-01-31
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
Ifetroban prevents and treats lung fibrosis due to multiple causes (bleomycin, genetic, radiation). The safety and efficacy of oral ifetroban will be assessed in patients with IPF.

Amendment record 23 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 23 times since 2022-10-04; most recent amendment 2026-03-03. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2024-02-01
Status change Not Yet Recruiting→Recruitingv7
Trial Details
NCT Number NCT05571059
Lead Sponsor Cumberland Pharmaceuticals
Conditions Idiopathic Pulmonary Fibrosis
Enrollment 128 participants
Start Date 2024-01-31
Primary Completion 2027-01 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-05